Atrium Therapeutics, Inc.
RNA
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | 19.64M | 859.00K | 1.57M | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 19.64M | 859.00K | 1.57M | ||
| Cost of Revenue | 10.80M | 14.29M | 6.32M | ||
| Gross Profit | 8.84M | -13.43M | -4.74M | ||
| SG&A Expenses | 20.26M | 15.67M | 2.09M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 36.92M | 29.96M | 9.03M | ||
| Operating Income | -17.28M | -29.10M | -7.45M | ||
| Income Before Tax | -16.63M | -29.10M | -7.45M | ||
| Income Tax Expenses | -- | 34.00K | -- | ||
| Earnings from Continuing Operations | -16.63M | -29.14M | -7.45M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -16.63M | -29.14M | -7.45M | ||
| EBIT | -17.28M | -29.10M | -7.45M | ||
| EBITDA | -17.13M | -28.98M | -7.40M | ||
| EPS Basic | -0.97 | -1.88 | -0.44 | ||
| Normalized Basic EPS | -0.61 | -1.17 | -0.27 | ||
| EPS Diluted | -0.97 | -1.88 | -0.44 | ||
| Normalized Diluted EPS | -0.61 | -1.17 | -0.27 | ||
| Average Basic Shares Outstanding | 17.11M | 15.52M | 17.11M | ||
| Average Diluted Shares Outstanding | 17.11M | 15.52M | 17.11M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||